Incyte Corporation INCY announced today that more than 35
analyses from clinical studies of Jakafi® (ruxolitinib) were
presented at the 2013 American Society of Hematology (ASH) Annual
Meeting from Dec. 7 to 10 in New Orleans. Jakafi, an oral JAK1/JAK2
inhibitor, is FDA-approved for the treatment of patients with
intermediate or high-risk myelofibrosis (MF).
“Myelofibrosis is a debilitating, life-threatening blood cancer with
limited treatment options. It is, therefore, rewarding to see that the
expanding body of clinical data for Jakafi shows durable reductions in
spleen volume and clinically meaningful improvements in health-related
quality of life measures and supports a survival benefit for patients,”
stated Paul A. Friedman, M.D., Incyte's Chief Executive Officer and
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in